interpersonal psychotherapy
BehavioralA 12-week intervention that focuses on resolving interpersonal stressors that are linked to the onset, maintenance or exacerbation of depressive symptoms
NCT Number: NCT02552836
The primary aim of this randomized controlled trial is to determine the acute antidepressant efficacy of interpersonal psychotherapy (IPT) in depressed patients with Parkinson's Disease.
Looking for future studies?
Notify Me18 year–85 year
All sexes
Interventional
Not applicable
The Ottawa Hospital, Ottawa, Ontario, Canada
The primary aim of this study is to determine whether IPT is more efficacious than an intervention that controls for non-specific factors (i.e., supportive psychotherapy) in reducing depressive symptoms. A secondary aim is to determine whether IPT is better than supportive therapy in improving quality of life, interpersonal functioning, attachment patters, and motor symptoms, and whether treatment gains are durable at 6-months follow-up. An exploratory aim of the study is identify moderators and mediators of treatment outcome. Patients who meet study criteria will be randomly assigned to either 12 sessions of IPT or 12 sessions of supportive therapy. The primary efficacy measure (Hamilton Depression Rating Scale) will be administered at baseline, weeks 6 and 12, and at 6 months follow-up.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
A 12-week intervention that focuses on resolving interpersonal stressors that are linked to the onset, maintenance or exacerbation of depressive symptoms
A 12-week intervention that focuses on non-specific factors that contribute to therapy outcome
Time frame: Change from baseline to week 12 and 6-months follow-up
17-item clinician rated scale that assesses severity of depressive symptoms
Time frame: Change from baseline to week 12 and 6-months follow-up
The BDI is a self report measure of depressive symptoms
Time frame: Change from baseline to week 12 and 6-months follow-up
The BAI is a self-report measure of anxiety symptoms
Time frame: Change from baseline to week 12 and 6-months follow-up
Self-report questionnaire that assesses quality of life in patients with Parkinson's Disease
Time frame: Change from baseline to week 12 and 6-months follow-up
Self-report inventory that measures aspects of interpersonal relationships
Time frame: Change from baseline to week 12 and 6-months follow-up
Self-report scale that assesses attachment style in adult relationships
Time frame: Change from baseline to week 12 and 6-months follow-up
Clinician rated scale that provides comprehensive coverage of motor symptoms in Parkinson's Disease
Hopital Montfort
Other
Evaluation of Two Psychotherapies for Depressed Patients With Parkinson's Disease
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04944017
Basal Ganglia Diseases, Behavior
New Haven, Connecticut, United States
View Trial DetailsNCT01931644
ADD/ADHD, Abnormalities, Multiple
Los Angeles, California, United States
View Trial DetailsNCT01437189
Basal Ganglia Diseases, Behavior
Hangzhou, Zhejiang, China
View Trial DetailsNCT02475954
Basal Ganglia Diseases, Behavior
Lyons, New Jersey, United States
View Trial Details